Central pancreatectomy for the treatment of a benign pancreatic lesion. Case report and literature review

Iván Domínguez-Sánchez, Ramón Gómez-Sanz, María Victoria Vieiro-Medina, Mónica Galán-Martín and Felipe de-la-Cruz-Vigo

Department of General and Digestive Surgery. Hospital Universitario 12 de Octubre. Madrid, Spain

ABSTRACT

We present the case of a 45 year old female patient with an incidental diagnosis of a cystic pancreatic lesion corresponding to a serous cystadenoma of 14 mm. During a 5-year follow-up (CT and MRT) the lesion tripled in size and a surgical intervention was decided upon. The lesion was thought to have a benign pathology and, in an attempt to preserve the spleen and a major portion of pancreatic tissue, a central pancreatectomy with a diversion of the remaining distal pancreas was carried out. The authors reviewed national and international publications.

Key words: Central pancreatectomy. Mesopancreatectomy. Benign pancreatic lesion.

INTRODUCTION

Central pancreatectomy (CP) is a pancreatic parenchyma-sparing technique, which can be used as a good alternative to major pancreatic resections such as distal pancreatectomy (DP). In the published studies CP was performed for benign lesions (neuroendocrine tumors, cystadenomas, small-size intraparenchymal tumors untreatable by enucleation, etc.) and for low-grade malignant lesions (mucinous cystic neoplasms, intraductal papillary mucinous neoplasms [IPMNs], solid pseudopapillary neoplasms, etc.) located in the neck and proximal body of the pancreas.

CP diminishes the morbidity related with major pancreatic resections with a lower incidence of pancreatic insufficiency, both of the endocrine and exocrine functions; it also decreases the risk of post-splenectomy infection.

Although there are multiple international studies in the literature, after review of published Spanish studies, we only found a few studies published by hospital centers in Navarra (1-6).
of the anastomosis was done with a liquid fibrin sealant and an aspiration drainage was placed in the proximity of the anastomosis.

There were no postoperative complications observed and the patient was discharged on the ninth day after surgery with normal blood glucose levels. The pathology study of the lesion confirmed the diagnosis of a serous cystadenoma.

After a 16-month follow-up, the patient remains asymptomatic, with no exocrine or endocrine pancreatic insufficiency, and has not been hospitalized as a consequence of the surgery.

DISCUSSION

Frequent use of imaging studies (ultrasonography and CT) as diagnostic techniques has led to an increase in the incidental discovery of pancreatic lesions, which are generally benign, asymptomatic and present a new challenge with regard to management and follow-up.

When it comes to dealing with benign lesions of the isthmus and proximal body of the pancreas which cannot be treated with enucleation (large lesions or lesions close to the duct of Wirsung), the usual techniques performed are a distal pancreatectomy (DP) or central pancreatectomy (CP) (3-5).

![Fig. 1. MRI showing a pancreatic cystic lesion of approximately 3.2 x 3 x 3.3 cm.](image)

### Table I

<table>
<thead>
<tr>
<th>Author</th>
<th>Number of cases of central pancreatectomy</th>
<th>Technique</th>
<th>Lesion type</th>
<th>Anastomosis type</th>
<th>Fistula rate</th>
<th>Pancreatic insufficiency rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rotellar et al.</td>
<td>9</td>
<td>9 laparoscopy</td>
<td>1 CS, 4 TNE, 3 QM, 1 IPMN</td>
<td>Pancreatejejunostomy: 100%</td>
<td>22.2%</td>
<td>0%</td>
</tr>
<tr>
<td>Iacono et al.</td>
<td>633</td>
<td>18 laparoscopy</td>
<td>121 QS, 147 TNE, 57 QM, 113 IPMN, 33 NQNE, 30 TPS, 9 MTR, 55 PCr5, 5 PQ, 63 others</td>
<td>Pancreatejejunostomy: 57.7%</td>
<td>0.9%</td>
<td>Exocrine: 11.9%</td>
</tr>
<tr>
<td>Goudard et al.</td>
<td>100</td>
<td>Conventional</td>
<td>3 QS, 35 TNE, 6Q M, 33 IPMN, 12 TPS, 3 QS, 2 PQ, 2 ECP, 4 others</td>
<td>Pancreatogastrostomy 100%</td>
<td>63%</td>
<td>Endocrine: 7%</td>
</tr>
<tr>
<td>Hirono et al.</td>
<td>24</td>
<td>24 Conventional</td>
<td>2 QS, 2 TNE, 2 QM, 16 IPMN, 1 TPS, 1 MTR</td>
<td>Pancreatejejunostomy: 21</td>
<td>62.5%</td>
<td>Exocrine: 4.7%</td>
</tr>
</tbody>
</table>

CS: Serous cystadenoma; TNE: Neuroendocrine tumor; QM: Mucinous cyst; IPMN: intraductal papillary mucinous neoplasm; NQNE: Non specified cystic neoplasm; TPS: Solid pseudopapillary tumor; MTR: Renal metastasis; QS: Simple cyst; PCr: Chronic pancreatitis; PQ: Pseudocyst; ECP: Pancreatic duct stenosis.
The classic approach with DP involves the complete resection of the body and tail of the pancreas; however, CP allows the preservation of the distal pancreas, without the need of a splenectomy. CP requires a central localization of the lesion, with the preservation of the pancreatic stump.

Central pancreatectomy, which was carried out for the first time by Dagradi and Serio, consists of the resection of the pancreatic isthmus followed by diversion of the stump by pancreatojejunostomy or by pacreatogastrostomy (1,2).

Different studies comparing both procedures (CP versus DP) have shown a higher incidence of short-term morbidity associated with CP. Among the complications, of note is the risk of pancreatic fistula of approximately 30-40%, which is related to the presence of two surgical borders in the case of CP (1,3,4). As these benign lesions are in normal pancreatic tissue, they tend to have a soft consistency and the duct of Wirsung tends to have a small diameter, which results in a higher risk of anastomotic leak. With regard to the fistulization risk related to the type of the pancreatic anastomosis, the cumulative incidence of fistula seems to be higher in the pancreatojejunostomy than in the pacreatogastrostomy; nevertheless, the first procedure has a lower risk of exocrine insufficiency. The reintervention risk for fistula is low (about 4%), meanwhile a conservative management gives good results (1,2,7,8).

Central pancreatectomy seems to reduce the intraoperative blood loss, but it is associated with an increase in the surgery time which is related to the meticulousness required in this type of procedure (1,3,9).

When evaluating long-term results, it is worth mentioning the benefit of CP in preserving the pancreatic function (6-7). According to the meta-analysis performed by Iacono et al. in 2013, the risk of endocrine insufficiency in CP was 5.5% versus 23.6% in the case of DP. With regard to exocrine function, the percentage would be 11.9% versus 19.1% (1,3). On a national level, the study performed by Herrera-Cabezón et al. should be mentioned, which reviews 480 pancreatic resections, among them ten CP. The indications for CP were three IPMNs, four cystadenomas and three neuroendocrine tumors. The fistula rate was 70-80%, which were managed in a conservative manner (8). Valenti-Azcárate et al. in 2005 described three cases of CP, two cases of mucinous cystadenoma and one of a serous cystadenoma (5).

With regard to the approach, conventional surgery is described in the majority of the studies, with the adaptation of the technique with laparoscopic and robot-assisted surgery (2,5,10). A series of nine laparoscopic central pancreatectomies, which had favorable results, published by Rotellar et al. in 2008 are worth mentioning (10).

CONCLUSION

Central pancreatectomy as a parenchyma preserving technique can be an excellent surgical option for patients with benign lesions or with low-grade malignant lesions (cystic or non-cystic) with a central location and with normal parenchyma. The high level of complexity of this technique should be noted, as well as the probable higher rate of pancreatic fistula during the postoperative period (1,3,5).

REFERENCES